Form 4: Allogene Therapeutics Director Joshua Kazam Awarded 94,500 Restricted Stock Units

Allogene Therapeutics, Inc. Director and 10% owner Joshua A. Kazam has been granted 94,500 Restricted Stock Units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• Joshua A. Kazam, a Director and 10% owner of Allogene Therapeutics, Inc. (ALLO), was granted 94,500 Restricted Stock Units (RSUs).
• The grant date for these RSUs was June 18, 2025.
• Each RSU represents a contingent right to receive one share of the company's Common Stock.
• The RSUs will vest in two successive equal semi-annual installments over a one-year period from the grant date.
• Vesting is contingent upon Mr. Kazam's continued service through the vesting dates.
• Following this transaction, Mr. Kazam beneficially owns 94,500 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a director's continued commitment and alignment with shareholder interests through equity compensation, which is a standard and expected corporate action.

Positives

• The grant of Restricted Stock Units to a director and 10% owner aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and continued service from the director.

Future Outlook

The document indicates that the granted Restricted Stock Units will vest in two equal semi-annual installments over a one-year period from the grant date of June 18, 2025, subject to the director's continued service.

Management Comments

• The Power of Attorney grants specific individuals the authority to execute Forms 3, 4, and 5 on behalf of the undersigned, an officer, director, or 10% holder, to ensure compliance with Section 16(a) of the Securities Exchange Act of 1934.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across all industries, including the biotechnology sector. It reflects standard corporate governance practices where directors receive equity awards to incentivize performance and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a common compensation practice in the biotechnology and pharmaceutical industries, similar to companies like Gilead Sciences, Amgen, or Regeneron Pharmaceuticals, where equity-based incentives are used to attract and retain top talent and align interests with company performance.
• The vesting schedule of two equal semi-annual installments over one year is a relatively short vesting period for director equity awards, which often range from one to four years, depending on the company's compensation philosophy and the specific role.

Corporate Governance

Related Party Transactions

• The grant of 94,500 Restricted Stock Units to Joshua A. Kazam, a Director and 10% owner, constitutes a related party transaction as it involves compensation provided to a key management personnel.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, as the value of the compensation is tied to the company's stock performance.
• Employees: While not directly impacting general employees, the compensation structure for directors can set a precedent for executive compensation practices within the company.

Next Steps

• The first semi-annual vesting of 47,250 RSUs is expected around December 18, 2025, subject to continued service.
• The second semi-annual vesting of 47,250 RSUs is expected around June 18, 2026, subject to continued service.

Key Dates

Keywords

Allogene Therapeutics, ALLO, SEC Form 4, Restricted Stock Units, RSU grant, insider ownership, director compensation, equity award, stock ownership, biotechnology, pharmaceuticals